The report addresses how the US’s decisions on the pandemic generally increased antimicrobial resistance, and the Centers for Disease Control and Prevention (CDC) recommendations for the future.
Although antimicrobial resistance infections went down steadily between 2017 and 2019, since the beginning of the pandemic in early 2020, the rates for AR infections have steadily increased. The decrease before the pandemic was, in part, due to the CDC’s emphasis on the importance of identifying and containing threats before they could spread. During the pandemic, however, with the focus on SARS-CoV-2, the threat of AR infections has been exacerbated by antibiotics being given—incorrectly—to nearly 80% of COVID-19 patients.
To address this concern, the CDC recently released a comprehensive 44-page report titled, “COVID-19 U.S. Influence on Antimicrobial Resistance: 2022 Special Report,” that discusses AR before and during the pandemic, and gives infection preventionists and United States health care a guide for positive progress to be made.
“We need everyone to hear that message loud and clear [that] antimicrobial resistance certainly did not go away during the pandemic. And this report demonstrates that, not only did it not go away, it actually got worse,” Captain Arjun Srinivasan, MD, Deputy Director for Program Improvement for the Centers for Disease Control and Prevention told Infection Control Today® (ICT®) in an exclusive interview.
Srinivasan told ICT® about the recommendations the CDC gives in the report on how to handle both AR and an emerging threat, such as COVID-19, simultaneously. “We have to build stronger public health data systems that will facilitate rapid exchange of information between the healthcare sector where that information is being gathered and public health officials who can you use that information to help bring resources to bear to solve problems, and then to get a better picture of where our problems actually are.”
Srinivasan also examines the increased use of electronic reporting, including for antibiotic use and resistance. “This is a big focus for CDC with our National Healthcare Safety Network. We do have the capability of monitoring antibiotic use and resistance fully electronically. And there are over 2400 hospitals that are submitting their antibiotic use data and more than 1000 hospitals that are submitting antibiotic resistance data to CDC. What an incredible start; we need to see all hospitals reporting that information that would give us such an important picture of antibiotic resistance in this country.”
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
Managing Multimorbidity and Polypharmacy in HIV: Insights From Michelle S. Cespedes, MD, MS
November 20th 2024Michelle S. Cespedes, MD, MS, discusses the challenges of managing multimorbidity and polypharmacy in HIV treatment, emphasizing patient education, evolving guidelines, and real-world insights from the REPRIEVE study.
Longhorn Vaccines and Diagnostics to Showcase Breakthrough Vaccine Data at IDWeek 2024
November 19th 2024Longhorn Vaccines and Diagnostics revealed promising data on universal influenza vaccine LHNVD-110 and AMR sepsis vaccine LHNVD-303 at IDWeek 2024, addressing critical global health challenges.